These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38007754)

  • 21. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: Immune lncRNAs predict prognosis of TNBC.
    Li YX; Wang SM; Li CQ
    Math Biosci Eng; 2021 May; 18(4):3939-3956. PubMed ID: 34198419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.
    Suo HD; Tao Z; Zhang L; Jin ZN; Li XY; Ma W; Wang Z; Qiu Y; Jin F; Chen B; Cao Y
    Biomed Res Int; 2020; 2020():7575862. PubMed ID: 32766313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioinformatics Analysis Identifies IL6ST as a Potential Tumor Suppressor Gene for Triple-Negative Breast Cancer.
    Jia R; Weng Y; Li Z; Liang W; Ji Y; Liang Y; Ning P
    Reprod Sci; 2021 Aug; 28(8):2331-2341. PubMed ID: 33650093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration.
    Ying B; Xu W; Nie Y; Li Y
    Dis Markers; 2022; 2022():8446857. PubMed ID: 36452344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a Group of Therapeutic Targets and Prognostic Biomarker for Triple Negative Breast Cancer.
    Li Y; Yang S; Qi L; Li Y; Wang X
    Adv Ther; 2024 Apr; 41(4):1621-1636. PubMed ID: 38421558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
    Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
    Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Key gene leading to poor prognosis of triple-negative breast cancer based on bioinformatics analysis].
    Yang R; Lu XQ; Wang FS
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(48):3874-3878. PubMed ID: 33371634
    [No Abstract]   [Full Text] [Related]  

  • 32. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
    Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
    Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
    Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
    BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
    Yan C; Liu Q; Jia R
    Front Oncol; 2022; 12():829045. PubMed ID: 35186763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Markers in Triple-Negative Breast Cancer.
    Sporikova Z; Koudelakova V; Trojanec R; Hajduch M
    Clin Breast Cancer; 2018 Oct; 18(5):e841-e850. PubMed ID: 30146351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
    Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
    Front Immunol; 2022; 13():964118. PubMed ID: 36059470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
    Liu Z; Ding M; Qiu P; Pan K; Guo Q
    Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZNF503 combined with GATA3 is a prognostic factor in triple-negative breast cancer.
    Liu S; Cao X; Li J; Liu J
    Biomarkers; 2023 Dec; 28(5):437-447. PubMed ID: 37036735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.
    Gao Y; Wang X; Li S; Zhang Z; Li X; Lin F
    Med Sci Monit; 2021 May; 27():e930025. PubMed ID: 34003815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer.
    Gul S; Pang J; Yuan H; Chen Y; Yu Q; Wang H; Tang W
    Sci Data; 2023 Nov; 10(1):815. PubMed ID: 37985782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.